Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

patienst who survived from breast cancer are prescribed long administraion of aromatase inhbitors.. these inhibitors usually induce musckloskeletal pains. Programmed phsyical activity are reommended to improve these pains but effects of HYperbaric oxygen on these pain was not investigated

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: hyperbaric therapy and exercise — Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) and additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.
  • Other: exercise — Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly for 2 month).

Primary Outcomes

  • visual analogue scale (it will be measured after 2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-07
Completion: 2026-09-01
Eligibility
Age: 65 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cairo University
Principal Investigators:
  • Ali MA Ismail, lecturer (PRINCIPAL_INVESTIGATOR) - Cairo University
Contact Information
Study Contact:
Ali MA Ismail, lecturer
01005154209
ali.mohamed@pt.cu.edu.eg
ali moahmed, lecturer
01031321109
fatmaraed1994@gmail.com
ali AM Ismail, lecturer
+201005154209
ali.mohamed@pt.cu.edu.eg
Cairo University
Interventions
  • Other: hyperbaric therapy and exercise — Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) and additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.
  • Other: exercise — Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly for 2 month).
Study Locations (1 sites)
Cairo University, Dokki, Giza Governorate 11432 Egypt
Eligibility Criteria
Inclusion Criteria: * braest cancer survivors * patients receiving aramatase inhibitor drugs * patients with musckolskeletal pains Exclusion Criteria: * cardiac patients * respiratory patients * renal patients
Conditions Triple-negative Breast Cancer, TNBC - Tr...
Phase PHASE2
Enrollment 61
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

About 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for individuals with TNBC to achieve a so-called pathologic complete response (pCR) to treatment. In the phase II study SAKK 66/22, it is being investigated whether the administration of the drug INT230-6 before surgery for breast cancer can increase the rate of pCR in the tumor and affected lymph nodes. The tolerability of INT230-6 as well as other factors such as response to treatment and the possibility of breast-conserving surgery are also being examined.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: INT230-6 — INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate. The IMP is without marketing authorization in Switzerland and anywhere in the world.
  • Other: neoadjuvant immuno-chemotherapy — Standard of care

Primary Outcomes

  • Pathological complete response (pCR) in the primary tumor (ypT0/Tis) and affected lymph nodes (ypN0). (At the date of tumor assessment after surgery, estimated at 29 to 32 weeks after treatment start for cohort A and at 27 to 30 weeks after treatment start for cohort B.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-24
Completion: 2031-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 61 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Swiss Cancer Institute
Principal Investigators:
  • Markus Joerger, Prof (STUDY_DIRECTOR) - HOCH Health Ostschweiz, Kantonsspital St. Gallen
  • Ursina Zürrer, MD (STUDY_CHAIR) - Kantonsspital Winterthur KSW
Contact Information
Study Contact:
Jana Musilova, PhD
+41 31 389 91 91
trials@swisscancerinstitute.ch
Olivier Tredan, MD
+33 4 78 78 26 44
olivier.tredan@lyon.unicancer.fr
Centre de lutte contre le cancer Léon Bérard
Olivier Tredan
Centre de lutte contre le cancer Léon Bérard
Interventions
  • Drug: INT230-6 — INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate. The IMP is without marketing authorization in Switzerland and anywhere in the world.
  • Other: neoadjuvant immuno-chemotherapy — Standard of care
Study Locations (10 sites)
Centre de lutte contre le cancer Léon Bérard, Lyon, 69008 France
Tumor Zentrum Aarau, Aarau, 5000 Switzerland
St. Claraspital, Basel, 4058 Switzerland
EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni, Bellinzona, 6500 Switzerland
Kantonsspital Graubünden, Chur, 7000 Switzerland
Kantonsspital Baselland, Liestal, 4410 Switzerland
HOCH Health Ostschweiz, Sankt Gallen, 9007 Switzerland
TBZO - Tumor- & Brustzentrum Ostschweiz, Sankt Gallen, 9016 Switzerland
Kantonsspital Winterthur, Winterthur, 8401 Switzerland
Universitätsspital Zürich - Klinik für Gynäkologie, Zurich, 8091 Switzerland
Eligibility Criteria
Inclusion Criteria: * Written informed consent according to country specific law and ICH GCP E6(R2) regulations before registration and prior to any trial specific procedures. * Newly histologically diagnosed, previously untreated locally advanced non-metastatic TNBC as defined by the most recent American Society of Clinical Oncology (ASCO) / College of American Pathologist (CAP) guidelines . * The following stages according to staging per American Joint Committee on Cancer (AJCC) for breast cancer staging criteria version 8 are included: cT1c (1.5-2cm) N1-3 M0 or cT2-4c N0-3 M0. * Multifocal and multicentric primary tumors are allowed and the tumor with the most advanced T stage should be used to assess eligibility. If multifocal or multicentric disease TNBC needs to be confirmed for each focus. * Measurable disease in the breast with at least one lesion with a diameter ≥ 1.5cm that is evaluable per RECIST v1.1, visible in ultrasound and injectable. * Male or female subject Age ≥ 18 years. * ECOG performance status 0-1 * Adequate bone marrow function (administration of G-CSF, EPO and/or blood transfusion within 14 days before registration is not allowed): * neutrophil count ≥ 1.5 x 109/L * platelet count ≥ 100 x 109/L * hemoglobin ≥ 90 g/L * Adequate hepatic function: * total bilirubin ≤ 1.5 x ULN, or direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 x ULN * AST and ALT ≤ 2.5 x ULN, * Albumin 30 ≥ g/L * Lactate Dehydrogenase (LDH) \<2.5 ULN * Adequate renal function: estimated glomerular filtration rate (eGFR) ≥ 50 ml/min/1.73 m2 (according to CKD-EPI formula) * Adequate cardiac function: Left ventricular Ejection Fraction (LVEF) ≥ 50% as determined by echocardiography (ECHO) * Adequate coagulation function: * INR ≤ 1.5 x ULN unless the patient is receiving anticoagulant therapy * aPTT ≤ 1.5 x ULN unless the patient is receiving anticoagulant therapy * If the patient is receiving anticoagulant therapy, the treating physician must determine that the anticoagulation can be stopped at least 24 hours prior to injection. * Women of childbearing potential must use highly effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and until 7 months after the last dose of INT230-6 or 6 months after standard of care treatment. A negative pregnancy test before inclusion into the trial is required for all women of childbearing potential. (www.swissmedicinfo.ch). * Men agree not to donate sperm or to father a child by using effective contraception during trial treatment and until 6 months after the last dose of INT230-6 or standard of care treatment (www.swissmedicinfo.ch). Exclusion Criteria: * Inflammatory Breast Cancer cT4d * Unfavorable relation between tumor size and breast size as determined by judgement of the treating physician, surgeon and/or investigator, where tumor shrinkage during neoadjuvant immunochemotherapy is required for breast conserving surgery to be considered. * Unfavorable tumor location that can potentially result in an unfavorable cosmetic outcome (e.g. high upper inner quadrant) and/or close skin contact by judgment of the treating physician, surgeon and/or investigator. * The following histological subtypes of TNBC are excluded: Classic adenoid cystic carcinoma, secretory carcinoma, low-grade adenosquamous carcinoma, tall cell carcinoma with reversed polarity, high-grade metaplastic * History of invasive malignancy ≤3 years prior to signing informed consent (except treated basal cell or squamous cell skin cancer or in situ cervical cancer) * Prior chemotherapy, targeted therapy, radiation therapy or anti-PD-L1 agent for previous breast cancer or Ductal Carcinoma in Situ (DCIS) on the same side. * Concurrent bilateral breast cancer * Concomitant treatment with any other experimental drug for recent breast cancer diagnosis in another clinical trial. * Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA II or IV; unstable angina pectoris, history of myocardial infarction and acute coronary syndrome requiring stenting/bypass surgery within the last six months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia), significant QT-prolongation, uncontrolled hypertension. * Known history of human immunodeficiency virus (HIV) or active chronic hepatitis C or hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment. * Active autoimmune disease that required systemic treatment in past 2 years (e.g., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroid hormone replacement, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. * History of (non-infectious) pneumonitis that required steroids or current pneumonitis. * Known history of tuberculosis. * Known history of allogeneic organ or stem cell transplant. * Receipt of live attenuated vaccine (including yellow fever vaccine) within 30 days prior to registration. * Diagnosis of immunodeficiency, concomitant or prior use of immunosuppressive medication within 7 days before registration, with the exceptions of local (intranasal, topical and inhaled) corticosteroids, or systemic corticosteroids which must not exceed 10 mg/day of prednisone or a dose equivalent corticosteroid, and the premedication for chemotherapy. * Concomitant anticoagulation with warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon), factor Xa inhibitors (e.g. rivaroxaban, apixaban), direct thrombin inhibitors (e.g. dabigatran) or platelet inhibitors/antiplatelet agents that cannot be stopped 24 hours before the administration of INT230-6. Aspirin (up to 300 mg/day) is allowed. * Any concomitant drugs contraindicated for use with the trial drug according to the Investigator Brochure (IB) and the immuno-chemotherapy treatment according to the approved product information. * Known hypersensitivity to trial drug or to any component of the trial drug or immuno-chemotherapy treatment. * Incapacitated adults and any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Conditions Breast Cancer, Breast Cancer - Female, B...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: SHIELD portal — All participants will receive access to the SHIELD portal. The portal includes educational modules, symptom and side effect tracking, tailored informational resources, and health behavior tools. Participants can access the portal via smartphone, tablet, or computer. The portal is HIPAA compliant and HITRUST certified.

Primary Outcomes

  • Enrollment Yield (up to 3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-04
Completion: 2027-05
Eligibility
Age: 18 Years – 49 Years
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: Breast Cancer Research Foundation
Principal Investigators:
  • Ann H Partridge, MD, MPH (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Ann H Partridge, MD, MPH
617-632-6800
ann_partridge@dfci.harvard.edu
Kate Dibble, Ph.D.
617-582-8294
katee_dibble@dfci.harvard.edu
Ann H Partridge, MD, MPH
617-632-6800
ann_partridge@dfci.harvard.edu
Dana-Farber Cancer Institute
Interventions
  • Behavioral: SHIELD portal — All participants will receive access to the SHIELD portal. The portal includes educational modules, symptom and side effect tracking, tailored informational resources, and health behavior tools. Participants can access the portal via smartphone, tablet, or computer. The portal is HIPAA compliant and HITRUST certified.
Study Locations (1 sites)
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion criteria Participants will be eligible if they meet the following eligibility criteria: * Female * Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer * Premenopausal * In active treatment (including long-term endocrine therapy) at the time of enrollment * Able to speak, understand and read English * Access to a US-based mobile phone number * Cognitively able to complete study requirements * Ability to access medical records from treating hospital (DFCI) * Willing to provide cell phone number and/or email address and willing to receive email, mobile push notifications, and/or text messages from the study team Exclusion criteria Participants will be ineligible if they meet any of the following criteria: * Individuals under age 18 or over age 50 at initial breast cancer diagnosis * Stage IV or metastatic breast cancer * Pregnant patients * Individuals who do not have a US mobile phone number * Males with breast cancer are not being recruited to this protocol. In the adolescent and young adult (AYA) age group, only a miniscule proportion of breast cancers occur in males. Additionally, this pilot focuses on breast cancer treatment utilizing OFS and ET, both of which do not apply to males. For this reason, the SHIELD portal intervention materials have been targeted for young women.
Conditions Breast Neoplasms
Phase PHASE3
Enrollment 192
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Gemcitabine, Vinorelbine, Eribulin, or Utidelone — Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.

Primary Outcomes

  • progression-free survival (PFS) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-09-15
Completion: 2028-06-24
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 192 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Contact Information
Study Contact:
Zhong-yu Yuan, M.D.
China: +86 20 87343009
yuanzhy@sysucc.org.cn
Zhong-yu Yuan, M.D.
86-20-87343794
yuanzhy@sysucc.org.cn
Sun Yat-sen University Cancer Center
Interventions
  • Drug: Gemcitabine, Vinorelbine, Eribulin, or Utidelone — Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.
Study Locations (1 sites)
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510080 China
Eligibility Criteria
Inclusion Criteria: * Understands and voluntarily signs the informed consent form. * ECOG PS of 0 or 1. * Expected survival: \>3 months * Histologically or cytologically confirmed advanced invasive breast cancer. * Histological type: HR+/HER2- or HR-/HER2-. HR positivity is defined as ER and/or PR expression in ≥1% of tumor cells by IHC. HER2 negativity is defined according to the ASCO-CAP HER2 guidelines: IHC intensity of 0 or 1+, or IHC intensity of 2+ with negative in situ hybridization results. * Previous failure of first-line treatment for metastatic disease. For HR+/HER2- patients: at least received endocrine therapy combined with CDK4/6 inhibitors. TNBC patients at least received chemotherapy combined with PD-1 inhibitors (if PD-L1 CPS ≥1), or PARP inhibitor treatment (if germline BRCA mutations), except for TNBC patients with known germline BRCA mutations whom the attending physician deems them unable or unsuitable for PARP inhibitor treatment. * At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. * Adequate organ function including bone marrow, renal function, hepatic function, and cardiac reserve. * Premenopausal women must use medically acceptable contraception during the study. * Compliance with the study protocol. Exclusion Criteria: * The investigator considers that the presence of the following factors would be unfavorable to the subject's participation in the study or may affect protocol compliance, such as uncontrolled hypertension, persistent or active infection, etc. * Persistent toxicities caused by previous anti-tumor treatment that have not improved to ≤ Grade 2 or baseline levels. * Neoplastic spinal cord compression or active brain metastases. * Significant third-space fluid retention (e.g., ascites or pleural effusion). * Uncontrolled infection requiring treatment with intravenous antibiotic. * Active or uncontrolled hepatitis B or hepatitis C virus infection. * Uncontrolled or significant heart disease. * Suspected ILD/non-infectious pneumonia. * Active autoimmune disease or inflammatory disease (including inflammatory bowel disease.
Conditions Breast Cancer, Neoadjuvant
Phase PHASE2
Enrollment 62
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel — Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles. Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles. Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given. Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration

Primary Outcomes

  • total Pathological Complete Response(tPCR) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-05-11
Completion: 2028-05-11
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 62 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Contact Information
Study Contact:
Yao Jing
13971139665
jeaneyph@163.com
Jing Yao
02785726375
jeaneyph@163.com
WuhanHU
Yao Jing
13971139665
jeaneyph@163.com
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Interventions
  • Drug: pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel — Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles. Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles. Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given. Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration
Study Locations (2 sites)
WuhanHU, Wuhan, Hubei 430000 China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei China
Eligibility Criteria
Inclusion Criteria: * Newly treated female patients aged ≥18 years and ≤75 years; * ECOG score 0\~1; * Pathologically diagnosed as HER2-positive breast cancer patients with early or locally advanced tumor stage, primary tumor diameter T≥2cm or lymph node positive; * Hormone receptor status (ER and PgR) is known, where ER≥10% * Normal function of major organs: 1. The standard of blood routine examination should meet: ANC ≥1.5×109/L; PLT≥90×109/L; Hb ≥90g/L 2. Biochemical examination should meet the following standards: TBIL≤ the upper limit of normal value(ULN); ALT and AST≤1.5 times the upper limit of normal (ULN); Alkaline phosphatase ≤2.5 times the upper limit of normal (ULN); BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (CockcroftGault formula); 3. Cardiac color ultrasound and echocardiography: left ventricular ejection fraction(LVEF≥55%) 4. Fridericia calibrated QT interval (QTcF) for 18-lead ECG \<470 ms; * For female patients who are not menopausal or have not been surgically sterilized: consent to abstinence or use of an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment; * Volunteer to join the study and sign the informed consent. Exclusion Criteria: * Stage IV (metastatic) breast cancer; * Inflammatory breast cancer; * Previous antitumor therapy or radiation therapy for any malignancies, excluding cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma; * Also receiving antitumor therapy in other clinical trials, including endocrine therapy, bisphosphonate therapy, or immunotherapy; * Had a major surgery not related to breast cancer in the 4 weeks prior to enrollment, or had not fully recovered from such surgery; * Serious heart disease or discomfort, including but not limited to the following: * History of heart failure or systolic dysfunction (LVEF \< 50%) * High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate \>100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia), or higher-grade atrioventricular block (i.e. Mobitz II second- degree atrioventricular block or third-degree atrioventricular block * Inability to swallow, intestinal obstruction, or other factors affecting the use and absorption of the drug; * Known allergic history of the drug components of this protocol; A history of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation; * Women who are pregnant or nursing, women who are fertile and have a positive baseline pregnancy test, or women of childbearing age who are unwilling to use effective contraception throughout the trial period and within 7 months after the last study medication; * Have a serious concomitant condition or other comorbid condition that interferes with planned treatment, or any other condition in which the investigator deems the patient unsuitable for participation in the study.

HER-2 B Cell Peptide Vaccine

NCT06414733
Recruiting
Conditions Metastatic Breast Cancer, HER2-positive ...
Phase PHASE1
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51 — Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 51 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 51, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.

Primary Outcomes

  • Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria 5.0 (through study completion (i.e. up to 1 year post initial vaccine))
  • Humoral Immune Response (through completion of 3 vaccine series (i.e. up to day 92 post final vaccine injection))
  • Overall Response Rate (through completion of 3 vaccine series (i.e. up to day 71))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-01-17
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pravin T.P Kaumaya
Principal Investigators:
  • Pravin Kaumaya, PhD (PRINCIPAL_INVESTIGATOR) - Indiana University
Contact Information
Study Contact:
Xin Bryan, RN
317-274-5495
zhongx@iu.edu
Xin Bryan, RN
317-274-5495
zhongx@iu.edu
Indiana University Melvin & Bren Simon Comprehensive Cancer Center
Pravin Kaumaya, PhD
Indiana University Melvin & Bren Simon Comprehensive Cancer Center
Interventions
  • Biological: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51 — Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 51 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 51, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
Study Locations (1 sites)
Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianpolis, Indiana 46202 United States
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria for Extension and Expansion Cohorts 1. For the extension cohort to be conducted at the IUSCCC (N=12), patients with histologically documented metastatic or unresectable breast or esophageal cancer will be enrolled. 2. For the expansion cohort (N=30), patients with either histologically documented metastatic or unresectable breast cancer (N=15), or histologically documented metastatic or unresectable esophageal cancer (N=15) be enrolled. All patients enrolled to this cohort are required to have measurable disease. Note: Measurable disease is defined as ≥ 1 lesions that can be accurately measured in ≥ 1 dimensions as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan. Inclusion Criteria for all Cohorts: 3. Patients must have received or refused first line standard systemic therapy for their metastatic/advanced disease. 1. Patients with histologically confirmed esophageal cancers must have received no more than two prior cytotoxic chemotherapy regimens in the last two years. 2. Patients with histologically confirmed breast cancers must have received no more than three prior cytotoxic chemotherapy regimens in the last two years. 4. Patients are required to have HER-2 (IHC 1+, 2+ and 3+) or EGFR over-expression (FISH and IHC) to be enrolled on this study. 1. If the patient has had HER-2 expression measured prior to enrollment, the report alone will be accepted on the expansion phase of the study. 2. If the patient has had EGFR expression measured prior to enrollment, the report alone will be accepted on the dose escalation phase of the study. 3. If the patient has not had HER-2 or EGFR expression measured prior to enrollment on this study, it would be obligatory for the patient to have the tests performed to justify their status. Any clinically approved assay is acceptable. The test can be done at IUSCCC or other CLIA-certified facility. 5. Patients with prior history of treated brain metastases who are off steroids and have stable metastatic brain disease for at least 3 months are eligible. 6. Patients must be ambulatory with ECOG performance status 0, 1, or 2 (appendix II). 7. Patients must have adequate organ function as defined by: 1. ANC ≥ 1,000/mm³, platelet count \> 700,000/mm³. 2. Serum bilirubin \< 1.5 mg%, regardless of whether patients have liver involvement secondary to tumor. ALT must be \< 3 times upper limit of normal. 3. Creatinine \<1.5 mg/dl or calculated creatinine clearance \> 60 ml/min 8. Patients must be at least 3 weeks past any prior surgery, cytotoxic, chemotherapy, other immunotherapy, hormonal therapy, or radiation therapy. Patients having been treated with monoclonal antibodies may enter the trial after a specified period of time (2 times the mean half life of the agent). Patients must have recovered (grade 1 or less) from any clinically significant toxicity of prior therapy prior to enrolling on study except for neuropathy where patients need to recover to grade 2 better. a. Patients with hormone receptor positive breast cancer who are on stable endocrine therapy are eligible if their tumor has some expression of HER-2 based on IHC of 1+ or 2+. 9. Patients must be at least 18 years of age. 10. Women of child-bearing potential must not be pregnant and must have a negative pregnancy test (Women of childbearing potential definition: (ECOG definition)). 11. Men and women of childbearing potential must agree to practice effective contraception while on this study. 12. Patients must obtain a base line Echocardiogram or MUGA and require the left ventricular ejection fraction to be within normal limits (or 50% or higher). 13. Ability to understand and the willingness to sign a written informed consent document. The patient must be aware that his/her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts. 14. Patients with a history of measles vaccination or infection. a. Patients with no measles vaccination history are eligible. Note: For patients with a history of measles vaccination or infection, they will be monitored for an hour during the skin test for hypersensitivity. Exclusion Criteria: 1. Patients with tumors that are negative for HER-2 expression based on IHC of 0 AND Fluorescence in-situ hybridization showing lack of HER-2 amplification based on most recent ASCO/CAP guidelines; or are under-expressing EGFR based on FISH and IHC. 2. Patients on targeted therapies, such as Cycline Dependent Kinase (CDK) 4/6 or mammalian target of rapamycin (mTOR) inhibitors in combination with endocrine therapy. 3. Patients who are {MVF-HER-2(266-296) and MVF-HER-2 (597-626)} immediate hypersensitivity skin test positive. 4. Patients who have evidence of active infection that requires parenteral antibiotic therapy. 5. Patients with known active HIV, hepatitis A, hepatitis B, or hepatitis C infection. 6. Patients with serious uncontrolled cardiopulmonary disorders, including congestive heart failure, symptomatic coronary artery disease, serious cardiac arrhythmia, and symptomatic chronic obstructive pulmonary disease or patients with other serious uncontrolled medical diseases. At the discretion of the treating physician, patients who show disease control for at least 6 months may be enrolled. 7. Patients who require or likely to require corticosteroids or other immunosuppressives for intercurrent disease are NOT eligible. 8. Splenectomized patients. 9. Patients with active autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis dermato-myositis, or a vasculitic syndrome. Note: At the discretion of the treating physician, patients who show disease control for at least 6 months may be enrolled. 10. Patients who have developed anaphylactic responses to other vaccines. Inclusion of Women and Minorities Both men and women and members of all races and ethnic groups are eligible for this trial. Our estimates for enrollment on the clinical trial are based on a total sample size of 42 patients, assuming that the study enrolls the full complement of 12 patients in the extension phase, and an additional 15 in each of the three disease-specific subgroups as part of the expansion phase of the trial.
Conditions Breast Cancer
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Based on the results of the phase Ib/II study, the investigators hypothesize that combining a RET inhibitor lenvatinib with endocrine therapy letrozole improves objective response and progression-free survival compared to fulvestrant alone in the second line setting in patients who have progressed on first line endocrine therapy incorporating a CDK4/6 inhibitor. Letrozole and fulvestrant are anti-hormonal drugs that have been proven to have activity and are considered standard therapies for hormone receptor positive breast cancer. The purpose of this study is to determine if the combination therapy of letrozole (an anti-hormonal drug) and lenvatinib (a targeted therapy), when compared to another anti-hormonal drug fulvestrant, is effective in patients with hormone receptor positive breast cancer. Preliminary studies have shown that approximately 50-60% of hormone receptor positive breast cancers over-express RET, and may therefore respond to treatment by a drug that blocks the RET pathway. An earlier study conducted at the National University Cancer Institute, Singapore (NCIS) on the combination of letrozole and Lenvatinib has shown promising results. Among patients in whom hormonal therapy and a CDK4/6 inhibitor no longer worked, about one-quarter of patients had meaningful disease control. The study also showed that patients tolerated the combination of Lenvatinib and letrozole well with manageable side effects. Based on the promising findings from the earlier study, this study seeks to compare the effectiveness of lenvatinib plus letrozole with another standard anti-hormone treatment drug called fulvestrant. In addition, investigators are studying how body reacts to the treatment as well as studying gene and protein changes in the tumour in response to treatment, which may in the future, help us tailor drug treatment for individual patients according to the patient's and/or the tumour's genetic or protein make-up.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Lenvatinib + Letrozole — Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity. Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities. Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled. Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing. For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake. There is no dose modifications for letrozole.
  • Drug: Fulvestrant — Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.

Primary Outcomes

  • Progression-free survival (PFS) of patients treated on lenvatinib and letrozole compared to single agent fulvestrant (30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-12-27
Completion: 2027-08
Eligibility
Age: 18 Years – 99 Years
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National University Hospital, Singapore
Collaborators: Eisai Co., Ltd.
Principal Investigators:
  • Soo Chin Lee (PRINCIPAL_INVESTIGATOR) - National University Hospital, Singapore
Contact Information
Study Contact:
Soo Chin Lee
6772 4629
soo_chin_lee@nuhs.edu.sg
Soo Chin Lee, MBBS, MRCP
+65 6779 5555
Soo_Chin_Lee@nuhs.edu.sg
Nationa University Hospital
Soo Chin Lee, MBBS, MRCP
Nationa University Hospital
Interventions
  • Drug: Lenvatinib + Letrozole — Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity. Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities. Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled. Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing. For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake. There is no dose modifications for letrozole.
  • Drug: Fulvestrant — Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
Study Locations (1 sites)
Nationa University Hospital, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: Patients may be included in the study only if patient meet all of the following criteria: * Female, age =\>18 years. * Histologic or cytologic diagnosis of breast carcinoma. * Estrogen receptor positive (defined as =\>1% on immunohistochemical staining) * Progressed on first-line palliative endocrine therapy plus CDK4/6 inhibitor as immediate prior line of endocrine therapy. Prior palliative letrozole is allowed. * Only one prior line of endocrine therapy in the metastatic setting. * No more than 1 prior line of chemotherapy in the metastatic setting. * Measurable disease by RECIST criteria. * ECOG 0-1. * Estimated life expectancy of at least 12 weeks. * Adequate organ function including the following: \- Bone marrow: Absolute neutrophil (segmented and bands) count (ANC) =\>1.5 x 109/L Platelets =\>100 x 109/L \- Hepatic: Bilirubin \<= 1.5 x upper limit of normal (ULN), ALT or AST\<= 2.5x ULN, (or \<=5 X with liver metastases) \- Renal: Creatinine \<= 1.5x ULN * Normal thyroid function on thyroid screen (fT4 and TSH). Patients who have thyroid dysfunction are eligible if thyroid function is optimally controlled. * Post-menopausal women. Post-menopausal status is defined either by Age =\> 60 years and one year or more of amenorrhea Age \<= 60 years and one year or more of amenorrhea (in the absence of ovarian suppression) and with estradiol and FSH levels consistent with menopause, Pre-menopausal women who are treated with medical ovarian suppression with post-menopausal levels of estradiol (institutional limits) at time of study entry and who will continue to be suppressed with 4-weekly LHRH agonist during study treatment may be enrolled. If these patients were previously on 12-weekly long-acting LHRH agonist, this has to be switched to 4-weekly LHRH agonist while the patient is on study treatment. * Signed informed consent from patient or legal representative. Exclusion Criteria: Patients will be excluded from the study for any of the following reasons: * HER2 positive tumors. * Treatment within the last 30 days with any investigational drug. * Prior therapy with fulvestrant. * Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy. * Major surgery within 28 days of study drug administration. * Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy. * Pregnancy. * Breast feeding. * Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator. * Non-healing wound. * Poorly controlled diabetes mellitus. * Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * Uncontrolled or symptomatic brain metastases, and/or brain metastases requiring steroids * History of significant neurological or mental disorder, including seizures or dementia. * Uncontrolled blood pressure (defined as persistent systolic BP \>140 mmHg or diastolic BP\>90mmHg) in spite of optimized regimen of antihypertensive medication * Presence of proteinuria defined as 24h urine collection of grade 2 and above (protein \>1.0g/24h) * Significant cardiovascular impairment: history of congestive heart failure greater that New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of study drug, or cardiac arrhythmia requiring medical treatment at screening. * Bleeding or thrombotic disorders or gastrointestinal bleeding event or active hemoptysis or use of anticoagulants such as warfarin or similar agents requiring therapeutic INR monitoring, or subjects at risk of severe hemorrhage. The degree of tumor invasion/infiltration of major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage / necrosis following Lenvatinib therapy. * Patients with baseline QTc interval \>480ms that persists despite correction of electrolyte abnormalities and/or discontinuation of concomitant medications that are known to prolong QTc interval.
Conditions Breast Cancer Stage IV, HER2-low Breast ...
Phase Not Applicable
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy. The overarching aim of the HER2-Ex PET trial is to study the role of precision imaging utilizing positron emission tomography (PET) with the HER2-specific tracer \[68Ga\]Ga-ABY-025 (hereafter referred to as HER2-PET) in enhancing treatment planning for patients with metastatic HER2-expressing breast cancer Patients will be allocated based on HER2-status on PET and biopsy. Patients with HER2-expressing lesions in a fresh or archived tumour biopsy will be treated with T-DXd. The study hypothesis is that PET/CT precision imaging with a contemporary HER2-radiotracer (\[68Ga\]Ga-ABY-025) can be used and can lead to a potentially better identification of patients who benefit from T-DXd treatment, thereby achieving improved treatment responses as well as fewer side effects. This study's diagnostic approach provides a more individualized treatment strategy. Additionally, this study can potentially give us a better biological understanding of HER2-expressing mBC.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Positron emission tomografy with [68Ga]Ga-ABY-025 — Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)

Primary Outcomes

  • Therapy-predictive role of HER2-PET for the clinical benefit of treatment with T-DXd in patients with HER2-expressing mBC (9-12 weeks (first response evaluation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-03
Completion: 2032-04-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Renske Altena
Collaborators: Karolinska Institutet, Affibody
Principal Investigators:
  • Renske Altena, MD PhD (STUDY_DIRECTOR) - Karolinska Institutet
Contact Information
Study Contact:
Thuy Tran, Associate Prof, PharmD, PhD
+46812377777
thuy.tran@regionstockholm.se
Renske Altena, Associate Professor, MD PhD
renske.altena@ki.se
Oscar Wiklander, MD PhD
0728449485
oscar.wiklander@regionstockholm.se.se
Karolinska University hospital
Interventions
  • Diagnostic Test: Positron emission tomografy with [68Ga]Ga-ABY-025 — Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)
Study Locations (1 sites)
Karolinska University hospital, Solna, 17176 Sweden
Eligibility Criteria
Inclusion Criteria: * Female patients age ≥18 years. * Metastatic or locally advanced breast cancer with disease progression after ≥ 1 line of chemotherapy in the palliative setting, or with disease relapse within six months after completion of (neo-) adjuvant chemotherapy. * The patient must be able and willing to provide written consent to participate in the study. * At least one metastatic lesion ≥ 10 mm is available for biopsy o Exception can be made when a recent biopsy is available (no more than 12 months old and without exposition to HER2-targeted therapy or local radiotherapy to the specific lesion). * At least one additional metastatic index lesion ≥ 10 mm for evaluation of treatment effect (according to RECIST v1.1) * WHO performance status ≤ 2. * Expected survival \> 12 weeks. * Contraceptives: Females of child-bearing potential must agree to use adequate contraception prior to study entry, for the duration of the study treatment phase and for six months after the last dose of \[68Ga\]Ga-ABY-025. Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices (IUDs), and copper IUDs. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Women must refrain from donating eggs during this same period. Should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. If a female participant is of child-bearing potential (females are considered not of childbearing potential if they are at least one year postmenopausal and/or surgically sterile), she must have a documented negative serum Pregnancy testing prior to each administration of the IMP is obligatory. Exclusion Criteria: * Contra-indications for treatment for trastuzumab deruxtecan and inability to undergo this treatment as per local treatment routines. * A previously documented metastatic tumor biopsy that was HER2-positive (IHC 3+ and/or HER2 gene amplification). * Other manifest malignancies except for basal cell carcinoma of the skin. * Inadequate cardiac, renal, bone marrow or liver function * Patients with increased risk of complications from biopsies, i.e. increased risk of bleeding, defined as * prothrombin time test (INR value) \>1.4, platelet count \<70 (109/l), activated partial thromboplastin time (APTT) \>30s. * known bleeding disorders such as haemophilia, von Willebrand disease or platelet disorders. * any anticoagulants or antiplatelet treatment that cannot be temporarily paused
Conditions Breast Neoplasm Malignant Female
Phase PHASE2
Enrollment 152
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%. This gave rise to doubts about the usefulness of traditional local treatments for such responders. Omission of surgery after vacuum assisted breast biopsy (VABB) as well omission of radiotherapy after conservative surgery would now seem to be reasonable alternatives to standard care for highly selected patients, in whom systemic treatments have provided the maximum response.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Omission of local therapies — Omission of surgery (arm A) or radiotherapy (arm B) in those patients who have had the maximum response by neoadjuvant treatments. Maximum responders are those patients with no evidence of residual disease after neoadjuvant treatment at imaging -including mammography, US evaluation and contrast imaging procedures (MRI and/or CEM)-, confirmed by VABB on marked site of ascertained lesion. This study is open to all patients with T1-2, N0-1, M0 HER2-positive or triple negative breast cancer, treated with neoadjuvant systemic treatment, irrespective of treatments delivered.

Primary Outcomes

  • Events-free survival (EFS) for each study arm. (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-25
Completion: 2035-07-25
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 152 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Principal Investigators:
  • Massimiliano Gennaro, MD (PRINCIPAL_INVESTIGATOR) - Fondazione IRCCS Istituto Nazionale Tumori Milan
Contact Information
Study Contact:
Massimiliano Gennaro, MD
+390223903246
massimiliano.gennaro@istitutotumori.mi.it
Kiara Muca
+390223903908
kiara.muca@istitutotumori.mi.it
Massimiliano Gennaro, MD
+390223903246
massimiliano.gennaro@istitutotumori.mi.it
Fondazione IRCCS Istituto Nazionale Tumori Milano
Interventions
  • Other: Omission of local therapies — Omission of surgery (arm A) or radiotherapy (arm B) in those patients who have had the maximum response by neoadjuvant treatments. Maximum responders are those patients with no evidence of residual disease after neoadjuvant treatment at imaging -including mammography, US evaluation and contrast imaging procedures (MRI and/or CEM)-, confirmed by VABB on marked site of ascertained lesion. This study is open to all patients with T1-2, N0-1, M0 HER2-positive or triple negative breast cancer, treated with neoadjuvant systemic treatment, irrespective of treatments delivered.
Study Locations (1 sites)
Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, 20133 Italy
Eligibility Criteria
Inclusion Criteria: * Women ≥ 18y. * Initial diagnosis of unifocal HER2-positive (regardless of HR status) or Triple-negative (HR positivity lower than 10% is allowed) T1-2, N0-1, M0 breast cancer. * Treated with neoadjuvant systemic treatment according to the center recommendations. * Maximum responders and/or complete pathological response proved by surgery. * Scheduled for breast conservation. * Giving specific informed consent. Exclusion Criteria: * One of the inclusion criteria missed. * Residual ductal carcinoma in situ (DCIS) at VABB and/or surgery. * Bilateral synchronous breast cancer. * Previous malignancy within 5 years. * BRCA1-2, PALB2 or p53 proven mutation carrier (VUS are exclusion criteria as well). * Patients unable to perform regular follow up.
Conditions Breast Neoplasm Female, Benign Breast Ne...
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

In cases with breast masses, Doppler resistive index values will be calculated for the mass and surrounding healthy tissue and the opposite healthy breast tissue, and their effect on distinguishing between benign and malignant masses will be evaluated.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • A Novel Approach to the Evaluation of Breast Masses Using Doppler Ultrasonography: Percentage Changes in Resistive Index Between the Mass and Surrounding Normal Parenchyma in Benign-Malignant Differentiation (3-4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-04
Completion: 2026-05-19
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ahmet Yesildag
Principal Investigators:
  • Ahmet Yeşildağ, Prof.Dr. (STUDY_DIRECTOR) - Karamanoğlu Mehmetbey Universty
  • Ahmet Yeşildağ, Prof.Dr. (STUDY_DIRECTOR) - Karamanoğlu Mehmetbey University
Contact Information
Study Contact:
Ahmet Yeşildağ, Prof.Dr
+905057728297
ahmetysd@hotmail.com
Gökçe Merve Arman, Dr.
+905058734762
gmerveturgut@gmail.com
Ahmet Yeşildağ, Prof.Dr
+905057728297
ahmetysd@hotmail.com
Karamanoğlu Mehmetbey University, KEAH
Interventions
N/A
Study Locations (1 sites)
Karamanoğlu Mehmetbey University, KEAH, Karaman, Lütfen Seçiniz. 70200 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Those with solid breast masses * Female patients * Those with pathology results Exclusion Criteria: * Hypovascular masses * Cystic breast masses * Cases with mastitis
Conditions Metastatic Breast Cancer, Locally Advanc...
Phase PHASE1, PHASE2
Enrollment 99
Locations 22 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

A Phase I/II, Open-label study to assess the safety, tolerability, pharmacokinetic, and antitumor efficacy of FWD1802 monotherapy in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer. This clinical trial aims to explore the role of FWD1802 in the ER+/HER2- advanced breast cancer patient population. The primary objectives are to address the following questions: Phase I Study: Determine the Recommended Phase II Dose (RP2D) and/or Maximum Tolerated Dose (MTD) of FWD1802 in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. Phase II Study: To evaluate the efficacy of FWD1802 at the RP2D in patients with ESR1-mutated ER-positive/HER2-negative locally advanced or metastatic breast cancer, using objective response rate (ORR) as the efficacy endpoint.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: FWD1802 — Eligible subjects will receive FWD1802 treatment according to their assigned dose cohort. Dose Escalation Phase: This phase is divided into a Single-Agent Lead-in Period (C0) and a Multiple-Dosing Period (C1). During the single-agent lead-in period, subjects will receive one dose on Day 1, followed by a 6-day dosing pause. In the multiple-dosing period, subjects will be administered FWD1802 once daily. Dose Expansion Phase: Subjects will receive FWD1802 once daily. Each 4-week period constitutes one treatment cycle. Treatment will continue for up to 2 years or until one of the following events occurs (whichever comes first): disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, initiation of new anti-cancer therapy, or death. Patients who remain in the study at the end of the 2-year treatment period and continue to derive clinical benefit may, upon agreement between the investigator and the sponsor, have the option to continue treatment.

Primary Outcomes

  • Phase I Study (Approximately 2 years)
  • Phase II Study (Approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-09-12
Completion: 2028-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 99 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Forward Pharmaceuticals Co., Ltd.
Principal Investigators:
  • Jian Zhang (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Limin Yin
18520159114
yinlm@forward-pharm.com
Fanfan Li
13855137365
693671174@qq.com
The Second Hospital of Anhui Medical University
Fei Xu
13711277870
Xufei@sysucc.org.cn
Sun Yat-sen University Cancer Center
Interventions
  • Drug: FWD1802 — Eligible subjects will receive FWD1802 treatment according to their assigned dose cohort. Dose Escalation Phase: This phase is divided into a Single-Agent Lead-in Period (C0) and a Multiple-Dosing Period (C1). During the single-agent lead-in period, subjects will receive one dose on Day 1, followed by a 6-day dosing pause. In the multiple-dosing period, subjects will be administered FWD1802 once daily. Dose Expansion Phase: Subjects will receive FWD1802 once daily. Each 4-week period constitutes one treatment cycle. Treatment will continue for up to 2 years or until one of the following events occurs (whichever comes first): disease progression, intolerable toxicity, withdrawal of informed consent, loss to follow-up, initiation of new anti-cancer therapy, or death. Patients who remain in the study at the end of the 2-year treatment period and continue to derive clinical benefit may, upon agreement between the investigator and the sponsor, have the option to continue treatment.
Study Locations (22 sites)
The Second Hospital of Anhui Medical University, Hefei, Anhui China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong China
Huizhou First Hospital, Huizhou, Guangdong China
Guangxi Medical University Cancer Hospital, Nanning, Guangxi China
The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan China
Xinxiang Central Hospital, Xinxiang, Henan China
Henan Cancer Hospital, Zhengzhou, Henan China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan China
Hubei Cancer Hospital, Wuhan, Hubei China
The Central Hospital of Yongzhou, Yongzhou, Hunan China
Eligibility Criteria
Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for enrollment in this clinical study: 1. Voluntarily participate in the clinical trial and sign the informed consent form. 2. Female, aged ≥18 years. 3. Able to provide blood samples for central laboratory testing of ESR1 mutation status and other biomarker assessments. Phase I Study: ESR1 mutation status will be tested retrospectively. Phase II Study: Only subjects with confirmed ESR1 mutations will be enrolled (see Appendix 5 for details). 4. Histologically or cytologically confirmed locally advanced or metastatic breast cancer that is ER-positive and HER2-negative. Criteria for ER positivity: Immunohistochemistry staining shows nuclear staining in ≥10% of tumor cells. Criteria for HER2 negativity: Immunohistochemistry staining intensity is 0 or 1+; if the intensity is 2+, it must be confirmed negative by in situ hybridization. 5. Confirmed in menopause and not caused by ovarian function suppression drugs, must meet one of the following criteria: Previous bilateral oophorectomy. Age ≥ 60 years. Age \< 60 years (subdivided into the following conditions): 1. Never received chemotherapy, ovarian function inhibitors, or SERM drugs (tamoxifen, toremifene), with amenorrhea ≥12 months, and E2 and FSH levels in the postmenopausal range. 2. Received chemotherapy resulting in chemotherapy-induced amenorrhea ≥12 months, with E2 and FSH levels in the postmenopausal range. 3. Using SERM drugs (tamoxifen, toremifene), with E2 and FSH levels in the postmenopausal range. 6. Premenopausal or perimenopausal female subjects must agree to receive and maintain treatment with ovarian function suppression (LHRH agonists) during the study treatment period (ovarian function suppression treatment must be initiated at least 14 days before the first dose of study drug). 7. Prior treatment history must meet the following requirements: 1. Disease progression during or intolerance to standard therapy, or unsuitability for standard therapy. 2. Previous adjuvant endocrine therapy for at least 2 years, with recurrence during treatment or within 1 year after completion; OR at least one line of endocrine therapy for the advanced stage, with progression after at least 6 months of maintenance therapy on any line of advanced endocrine therapy (no limit on the number of endocrine therapy lines). 3. Previous chemotherapy for the advanced stage is ≤ 2 lines. 4. Prior use of fulvestrant, with an interval of at least 6 weeks between the last dose of fulvestrant and the first dose in this study. 5. An interval of at least 6 weeks is required between the last dose of prior tamoxifen and the first dose in this study. 6. Previous treatment with CDK4/6 inhibitors is ≤ 1 line. 8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (see Appendix 1 for details). 9. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Tumor lesions that have previously received radiotherapy or other local-regional treatment can only be considered measurable lesions if disease progression is confirmed. 10. Expected survival ≥ 3 months. 11. Subjects must have adequate organ and bone marrow function at screening (no blood transfusion, human albumin administration, or use of hematopoietic growth factors within 7 days prior to screening tests), defined as follows: 1. Complete Blood Count: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L. White blood cell count (WBC) ≥ 3.0 × 10⁹/L and ≤ 15 × 10⁹/L. Platelet count (PLT) ≥ 100 × 10⁹/L. Hemoglobin (HGB) ≥ 100 g/L. 2. Liver Function: Serum total bilirubin (TBIL) ≤ 1.5 × ULN. For subjects without liver metastases: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN. For subjects with liver metastases: ALT and AST ≤ 5 × ULN. 3. Renal Function: Serum creatinine (Scr) ≤ 1.5 × ULN OR creatinine clearance (Clcr) calculated by the Cockcroft-Gault method ≥ 50 mL/min. 4. Coagulation Function: Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN (for subjects on anticoagulant therapy, values should be within the therapeutic range): 1. For patients receiving warfarin, INR must be stable between 2.0 and 3.0. 2. For patients receiving heparin, APTT should be between 1.5 and 2.5 × ULN (or returned to the value prior to starting heparin therapy). 3. For prosthetic heart valves requiring anticoagulation, a stable INR between 2.5 and 3.5 is allowed. 5. Cardiac Function: Left ventricular ejection fraction (LVEF) \> 50% as shown by echocardiography. 12. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and must be non-lactating. Women of childbearing potential must agree to use effective contraceptive methods from the time of signing the informed consent form until 6 months after the last dose of the study drug. Effective methods include double barrier methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female subjects will be considered of childbearing potential unless they are naturally postmenopausal, have undergone artificial menopause, or have undergone sterilization (e.g., hysterectomy, bilateral salpingo-oophorectomy). Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from the study: 1. Leptomeningeal metastases, carcinomatous meningitis, spinal cord compression, or symptomatic or clinically unstable central nervous system (CNS) metastases. 2. History of ongoing gastrointestinal diseases or other malabsorptive conditions that may impact the absorption of orally administered study drugs, including but not limited to: 1. Inability to swallow oral medications. 2. Requirement for intravenous nutrition. 3. Prior surgery affecting absorption, including total/partial gastrectomy. 4. Crohn's disease, ulcerative colitis. 5. Treatment for active peptic ulcer disease within 6 months prior to the first dose. 6. Malabsorption syndrome, or uncontrolled nausea, vomiting, or diarrhea. 3. Patients with symptomatic visceral metastases, or those with clinically significant and unstable pleural, peritoneal, pericardial effusions, or pulmonary lymphangitic carcinomatosis. Patients who have received intracavitary infusion therapy or drainage/paracentesis may be enrolled 14 days or more after the effusion has stabilized. Other conditions deemed by the investigator as unsuitable for endocrine therapy. 4. Prior treatments do not meet the following washout periods: 1. Use of other investigational drugs or devices within 4 weeks prior to the first dose. 2. Treatment with CDK4/6 inhibitors or mTOR inhibitors within 2 weeks, or other targeted therapies, chemotherapy, or immunotherapy within 4 weeks prior to the first dose. 3. Radiotherapy, endocrine drugs, or traditional Chinese medicines with anti-tumor indications within 2 weeks prior to the first dose (washout periods for fulvestrant and tamoxifen refer to Inclusion Criterion 7). 4. Treatment with mitomycin or nitrosoureas within 6 weeks prior to the first dose. 5. Use of drugs or herbal supplements known to be moderate/strong inhibitors or inducers of CYP3A4 within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose (see Appendix 4). 6. Use of drugs that inhibit gastric acid production within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose (see Appendix 4). 7. Use of drugs that are P-glycoprotein (P-gp) inhibitors within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose (see Appendix 4). 5. Toxicities from prior anti-tumor therapy have not recovered to Grade ≤1 (except for alopecia, and chemotherapy-induced peripheral neuropathy ≤
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase NA
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial aims to see if patients with triple negative breast cancer can complete a biobehavioral stress reduction program that also addresses health related social needs (e.g., utilities, transportation, etc.). The stress reduction program is over ten weeks and includes stress reduction (e.g., progressive muscle relaxation), coping, problem solving, communication, and social support. Health related social needs will be evaluated at the beginning of the study, and referrals will be made to social work to help address those needs. The study will examine stress as reported by the patients and also use biological markers.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Medical Chart Review — Undergo medical cart review
  • Procedure: Stress Management Therapy — Receive biobehavioral stress reduction intervention
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Participant Satisfaction with the Biobehavioral Intervention (Up to 2 years)
  • Profile of Mood States for the Biobehavioral Intervention (Up to 2 years)
  • Participant Biobehavioral Intervention (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-12-14
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University Comprehensive Cancer Center
Principal Investigators:
  • Samilia Obeng-Gyasi, MD, MPH (PRINCIPAL_INVESTIGATOR) - Ohio State University Comprehensive Cancer Center
Contact Information
Study Contact:
The Ohio State Comprehensive Cancer Center
800-293-5066
OSUCCCClinicaltrials@osumc.edu
Natalie Joseph, MD
216-778-7800
MetroHealth
Samilia Obeng-Gyasi, MD, MPH
614-293-6408
samilia.obeng-gyasi@osumc.edu
Ohio State University Comprehensive Cancer Center
Interventions
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Medical Chart Review — Undergo medical cart review
  • Procedure: Stress Management Therapy — Receive biobehavioral stress reduction intervention
  • Other: Survey Administration — Ancillary studies
Study Locations (2 sites)
MetroHealth, Cleveland, Ohio 44109 United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Age \>=18 years * Untreated newly diagnosed triple negative breast cancer * Stages I-III Exclusion Criteria: * Prisoners * Male * Identifying as American Indian, Alaska Native, Asian, Native Hawaiian or Other Pacific Islander * Individuals not able to speak and understand English * Known personal history of ductal carcinoma in situ (DCIS) or invasive breast cancer * Stage IV breast cancer